Is Johnson & Johnson (JNJ) a Buy Right Now?
A plain-English read on Johnson & Johnson stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
Johnson & Johnson is currently trading at $260.86, showing a modest daily gain of 0.41%. The stock is in an upward trend, sitting comfortably above its 200-day average of $232.48. This suggests that the long-term direction of the company remains positive for those watching the broader market movement.
The RSI, or Relative Strength Index—a gauge of whether a stock has climbed too far, too fast—sits at 57.1. This level indicates the stock is neither overbought nor oversold. With the price currently positioned between the $250.44 floor and the $274.9 ceiling, the data supports a buy decision.
Should you buy Johnson & Johnson stock?
The data confirms a buy status based on the current upward trend and price positioning. While this is a buy, remember that markets move daily and no investment is without risk. Always consider your personal goals before adding a position to your holdings.
Is JNJ a good stock for beginners?
JNJ is often viewed as a stable choice due to its massive size and established history. With a P/E ratio—a measure of price relative to earnings—of 23.7, it is a standard starting point for those learning how to evaluate company value.
What's driving JNJ right now
The stock is currently trading above its 200-day average of $232.48, signaling positive momentum.
The stock has established recent support at $250.44, which acts as a foundation for the current price.
The RSI of 57.1 shows the stock has room to move without being considered overextended.
The price is moving toward its recent resistance level of $274.9, which may act as a temporary barrier.
What Johnson & Johnson actually does
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson & Johnson by the numbers
Wall Street consensus on JNJ is Buy. That is the analyst community's view, shown for context — it is not our read and not a recommendation.
Johnson & Johnson's earnings history
Earnings per share for Johnson & Johnson's last 4 reported financial years, as filed — EPS has risen over that span. We don't hold analyst consensus estimates for these periods, so no beat-or-miss judgement is shown.
| Period end | EPS reported |
|---|---|
| 2025-12-28 | 11.03 |
| 2024-12-29 | 5.84 |
| 2023-12-31 | 13.88 |
| 2023-01-01 | 6.83 |
Who owns Johnson & Johnson?
Institutions — pension funds, asset managers, index providers — hold 77.0% of JNJ, and the concentration matters: the largest single holder alone controls 8.85% of the company.
| Holder | Shares | % held |
|---|---|---|
| 213.39M | 8.85% | |
| 156.61M | 6.50% | |
| 133.48M | 5.54% |
Names withheld — plus 3 more records not shown.
See who owns itWhat Johnson & Johnson insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for Johnson & Johnson, 3 were sales and 0 were open-market purchases; the other 3 were awards, vesting or option exercises rather than a decision to buy or sell. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-20 | SELL | 23.1K | $5.8M | |
| 2026-07-20 | AWARD / VEST | 23.1K | $3.0M | |
| 2026-06-11 | SELL | 10.0K | $2.4M |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading JNJ?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. At least 25 disclosures name JNJ — filed by 12 separate members or more and worth $222K–$855K combined (filings report bands, never exact amounts). 7 purchase-side, 18 sale-side, most recently on 2026-06-29.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2026-06-29 | SELL | $1,001 - $15,000 | |
| 2026-06-09 | BUY | $1,001 - $15,000 | |
| 2026-06-02 | SELL | $1,001 - $15,000 |
Names withheld — plus 22 more records not shown.
See which membersWith the price holding above its 200-day average, Johnson & Johnson remains a buy for those seeking a steady, trend-following investment.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice JNJ risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about JNJ
Should I buy JNJ stock?+
The current data supports a buy, as the stock is trending upward and trading above its 200-day average of $232.48.
Is JNJ a good long-term investment?+
The stock is currently in an upward trend, trading at $260.86, which is well above its 52-week low of $173.33.
Is JNJ a buy or a sell?+
Based on the current price of $260.86 and the positive trend indicators, the data points to a buy.
Is JNJ overvalued?+
With a P/E ratio of 23.7 and a current price of $260.86, the stock is trading within its 52-week range.
Is JNJ a good stock for beginners?+
JNJ is a large, established company currently trading above its 50-day average of $253.82, making it a common choice for new investors.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold Johnson & Johnson (JNJ) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-08-12 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.